Skip to main content
. 2019 Aug 20;10(49):5041–5051. doi: 10.18632/oncotarget.27118

Figure 1. Quantitative assessment of EPCs in BRCA positive carriers and negative carriers.

Figure 1

Boxplots comparing the fraction of EPCs as a proportion of total PMNC between BRCA positive (Orange) and Negative (Blue) participants. (A) EPCs are identified as CD34+/VEGF+ cells by flow cytometry. (B) EPCs are identified as CD133+/VEGF+ cells by flow cytometry.